Standout Papers

A gut microbial signature for combination immune checkpoint blockade across cancer types 2024 202654
  1. A gut microbial signature for combination immune checkpoint blockade across cancer types (2024)
    Ashray Gunjur, Yan Shao et al. Nature Medicine

Immediate Impact

3 by Nobel laureates 7 from Science/Nature 72 standout
Sub-graph 1 of 22

Citing Papers

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
2025 Standout
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
3 intermediate papers

Works of Damien Kee being referenced

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
2020
Immunotherapy of melanoma
2016

Author Peers

Author Last Decade Papers Cites
Damien Kee 846 558 93 215 43 1.2k
Eduard Gasal 978 699 227 293 45 1.5k
Alberto Pisacane 613 475 263 240 48 1.3k
J. J. Bonerandi 774 459 46 105 23 1.4k
Andreas Kaubisch 573 493 124 115 66 1.3k
Lei Cai 667 504 337 294 51 1.3k
E. Lin 582 511 265 256 45 1.7k
Edward McKenna 772 754 158 77 41 1.3k
Thea M. Vroom 416 441 125 160 26 1.4k
Shannon McDonough 963 304 293 179 35 1.2k
Cécile Pagès 779 292 37 78 51 1.0k

All Works

Loading papers...

Rankless by CCL
2026